BALPHARMA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 23/100 — Quality 22 · Valuation 38 · Momentum 0
| Share price | ₹90.67 |
| Market cap | ₹126 Cr |
| P/E ratio | 19.7 |
| P/B ratio | 1.5 |
| ROE | 39.4% |
| ROCE | 18.0% |
| Dividend yield | 1.51% |
| Book value | ₹51.71 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹312 Cr | ₹6 Cr | 10.0% |
| 2025 | ₹303 Cr | ₹7 Cr | 10.0% |
| 2024 | ₹339 Cr | ₹7 Cr | 9.0% |
| 2023 | ₹304 Cr | ₹3 Cr | 8.0% |
| 2022 | ₹281 Cr | ₹6 Cr | 9.0% |
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate